Clinical trial
Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00041093 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00041093 |
|---|---|
| Title | Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer |
| Official title | A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma |
| Intervention type | Drug |
| Interventions | Docetaxel |
| Enrollment | 27 |
| Start date | Jun 1, 2002 |
| Primary completion | Oct 23, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: